Healthcare >> Analyst Interviews >> November 14, 2011

Orphan Drugs Bypass Macroeconomic Headwinds – Ian Somaiya – Piper Jaffray & Co.

Somaiya, Ian
Ian Somaiya is a Managing Director and Senior Research Analyst at Piper Jaffray & Co., covering the biotechnology industry. Prior to joining Piper Jaffray & Co. in 2010, Mr. Somaiya worked in equity research at Thomas Weisel Partners. Mr. Somaiya was recognized as Best on the Street by The Wall Street Journal in 2006, 2007 and 2009 for his biotechnology coverage. Formerly, Mr. Somaiya was a Senior Analyst at Morgan Stanley with responsibilities for small and midcapitalization biotechnology companies. He spent a year with The Carson Group in its healthcare consulting practice prior to making his transition to the sell side at Prudential Securities. Mr. Somaiya received a Bachelor of Arts in biology/neuroscience from New York University. Profile
TWST: We continue to hear that pharma and biotech are converging. What is your take on that?

Mr. Somaiya: I think the lines have blurred. Pharmaceutical companies have made a decision to move into the